Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
5.12
-0.13 (-2.48%)
At close: Jan 21, 2025, 4:00 PM
5.22
+0.10 (1.95%)
After-hours: Jan 21, 2025, 5:20 PM EST
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 131 employees as of September 30, 2024. The number of employees decreased by 14 or -9.66% compared to the previous year.
Employees
131
Change (1Y)
-14
Growth (1Y)
-9.66%
Revenue / Employee
$516,298
Profits / Employee
-$885,840
Market Cap
108.51M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ENTA News
- 13 days ago - Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - Business Wire
- 2 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 - Business Wire
- 4 months ago - Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) - Business Wire
- 5 months ago - Enanta Pharmaceuticals to Participate in Investor Conferences in September - Business Wire
- 6 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter - Business Wire